A major contributor to the lack of medicines in developing countries is an intellectual property regime that allows proprietary drug companies with intellectual property monopolies to charge high prices and maximize profit.
People with mental illness or a degenerative mental disease have special protections under the law when entering into contracts or other binding documents.